For instance, the Violette trial is an ongoing study with olaparib monotherapy versus olaparib in combination with an inhibitor of ATR (ceralasertib [AZD6738]) and olaparib monotherapy versus olaparib in combination with an inhibitor of WEE1 (adavosertib [AZD1775]), in the second- or third-line setting, in patients with triple-negative breast cancer prospectively stratified by qualifying tumor mutations in genes involved in the HRR pathway [60]. The gene discussed is WEE1; the disease is triple-negative breast carcinoma.